Boole Investment Syndicate
VC Fund
Cork, Ireland
Boole Investment Syndicate is a VC fund in Cork focused on Biotechnology and SaaS. Boole Investment Syndicate invests in new technology start-up's with scalability.
- Total investments:
- 10
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Boole Investment Syndicate invests in
Stages Boole Investment Syndicate invests in
Countries Boole Investment Syndicate invests in
Round sizes
Round size
- Seed
- $623k–$2.2M
Investment Focus
Industry
- Biotechnology 3 (30%)
- SaaS 2 (20%)
- Software 2 (20%)
- Medical Device 2 (20%)
- EdTech 1 (10%)
Stage
- Seed 5 (50%)
- Funding Round 2 (20%)
- Series A 1 (10%)
- Venture - Series Unknown 1 (10%)
Country
- Ireland 5 (50%)
- Estonia 1 (10%)
- United States 1 (10%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
ArrayPatch
|
ArrayPatch is a biotech company that specializes in clinical development services. | $2.2M / Seed / Feb 05, 2026 | |
eID easy
|
eID Simple assists businesses in adopting high-quality electronic signatures by collecting local, popular, and proven signature techniques where user identification is already confirmed to keep signing process friction to a minimum and price fair. | $1.5M / Seed / Oct 13, 2025 | |
Ovagen
|
Ovagen is a biotechnology company that has developed the process of producing germ free (GF) chicken eggs and GF birds in commercial quantities for use primarily in the pharmaceutical industry. Ovagen can also provide a Contract Research Service and has extensive expertise in SPF poultry & rodent housing & husbandry, in specific poultry& rodent research technologies to GMP standards and in avian transgenics. | $2.2M / Series A / Oct 29, 2024 | |
SymPhysis Medical
|
SymPhysis Medical's goal is to develop innovative technologies that treat a range of chronic diseases, putting the patient experience at the forefront of our design solutions to improve quality of life.About SymPhysis MedicalSymPhysis Medical's emergent technology, releaze, is a drainage technology to treat a common complication oflate-stage cancers, malignant pleural effusion (MPE). MPE causes significant shortness of breath and chest pain in up to 15% of patients with cancer. | $2.4M / Venture - Series Unknown / Oct 07, 2024 | |
|
SymPhysis Medical
|
SymPhysis Medical's goal is to develop innovative technologies that treat a range of chronic diseases, putting the patient experience at the forefront of our design solutions to improve quality of life.About SymPhysis MedicalSymPhysis Medical's emergent technology, releaze, is a drainage technology to treat a common complication oflate-stage cancers, malignant pleural effusion (MPE). MPE causes significant shortness of breath and chest pain in up to 15% of patients with cancer. | $1.7M / Seed / Dec 21, 2023 | |
FeelTect
|
FeelTect’s technology, Tight Alright, is a pressure sensing, connected-health device for measuring and monitoring sub-bandage pressure during compression therapy, primarily for the millions of people worldwide with venous leg ulcers (VLUs). Compression is a proven therapy for VLUs, however if it’s applied too loose, it’s ineffective, and if it’stoo tight, it’s dangerous. | $1.6M / Dec 20, 2023 | |
|
FeelTect
|
FeelTect’s technology, Tight Alright, is a pressure sensing, connected-health device for measuring and monitoring sub-bandage pressure during compression therapy, primarily for the millions of people worldwide with venous leg ulcers (VLUs). Compression is a proven therapy for VLUs, however if it’s applied too loose, it’s ineffective, and if it’stoo tight, it’s dangerous. | $1.6M / Seed / Dec 20, 2023 | |
Hooke Bio
|
Hooke Bio is a new Pharmaceutical company operating in the preclinical to early stages of drug discovery. It draws its strength from the close co-operation it has between its biologists and engineers. The engineers design, patent and test new microfluidic technology: the scientists apply the technology to finding new therapeutics. | $623.1K / Seed / Jun 01, 2022 | |
GoContractor
|
GoContractor is a digital onboarding and subcontractor management platform designed to get construction workers on site faster, reduce compliance risk, and improve safety, while driving productivity and profitability. Using GoContractor allows construction workers and subcontractors to get on site 3x faster all while digitizing worker records,making them searchable and accessible from anywhere. | $549K / Aug 08, 2019 | |
|
Hooke Bio
|
Hooke Bio is a new Pharmaceutical company operating in the preclinical to early stages of drug discovery. It draws its strength from the close co-operation it has between its biologists and engineers. The engineers design, patent and test new microfluidic technology: the scientists apply the technology to finding new therapeutics. | $878K / Seed / Dec 05, 2018 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Boole Investment Syndicate invest in?
Boole Investment Syndicate invests primarily in Biotechnology, SaaS and Software startups, most often at Seed and Funding Round stage. Most of the 10 investments tracked by Shizune back companies in Ireland. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Boole Investment Syndicate's check size?
Boole Investment Syndicate typically joins rounds of $623k–$2.2M at Seed. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Boole Investment Syndicate participates in.
When did Boole Investment Syndicate last invest?
The most recent investment recorded for Boole Investment Syndicate closed in Feb 2026. Shizune tracks 10 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
